Lexaria Bioscience Corp. has received a notification from the Nasdaq Stock Market indicating that the company is not in compliance with the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market. The company has 180 calendar days, until August 3, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. If compliance is not regained within this period, Lexaria may be eligible for an additional 180-day extension, provided it meets other listing requirements and notifies Nasdaq of its intent to cure the deficiency, potentially through a reverse stock split. Failure to comply could result in delisting, though the company would have the opportunity to appeal the decision.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001640334-26-000230), on February 06, 2026, and is solely responsible for the information contained therein.